The standardized regenerative process is the future alternative for the organ transplantation medicine. ORGANTRANS aims to develop a disruptive alternative to donor organs for patients with chronic end-stage liver diseases, especially those patients that have residual healthy tissue, which could be used for isolation of autologous adult liver stem cells from. The aim will be achieved by through the following elements / specific objectives:

  • Cell source for tissue engineering
  • Genomic and proteomic profiling of standardized spheroids
  • Spheroid sorter
  • Hydrogel bioink for tissue engineering
  • Bioprinting platform
  • Vascularization architecture
  • Bioreactor for construct maturation on disposable substrate
  • Construct maturation and in vitro testing
  • In vivo testing of the liver tissue transplant